Overview

A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Clozapine